Pharmacokinetic interaction study [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2016-05-19 12:05 (3193 d 23:20 ago) – Posting: # 16332
Views: 3,061

Dear Mahesh M
If you develop a new FDCP (and not a generic of another FDCP) you are obliged to investigate possible DDI. AFAIK/my experience: A DDI study is not a konfirmatory study, you only need to describe the pharmacokinetic interaction by means of each single entity and the same statistical confidence intervals. But you do not need to show bioequivalence by means of the acceptance range of 80-125%. If you meet the bioequivalence criteria everything is fine. If you are not (strictly) bioequivalent, you need to discuss the results with respect to risk and benefit of the new FDCP. However, if your new FDCP is a combination of two inhaler drugs in a same capsule I do not think that a simple DDI study would be sufficient since the systemic availability of the drugs might not reflect their combined local effect. A clinical phase III study can not be avoided.
I hope this helps.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
82 visitors (0 registered, 82 guests [including 12 identified bots]).
Forum time: 10:26 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5